SCHEMBL1247110

SCHEMBL1247110

[c]1cccc(-c2cccc3ccccc23)c1SCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.40
HPGD P15428 1/20 0.37
SIRT2 Q8IXJ6 2/20 0.37
MAPT P10636 3/20 0.36
CYP1A2 P05177 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP3A4 P08684 1/20 0.36
HIF1A Q16665 1/20 0.36
SSTR4 P31391 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALPL P05186 1/20 0.36
GAA P10253 1/20 0.36
S100A4 P26447 1/20 0.35
ELANE P08246 1/20 0.35
MAOB P27338 1/20 0.35
TERT O14746 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1724293 0.81 ELANE (0.35) TDP1HPGDMAPTCYP1A2ALDH1A1
SCHEMBL6981693 0.76 LMNA (0.39) TDP1HPGDMAPTCYP1A2ALDH1A1
SCHEMBL24245 0.74 APP (0.35) CYP3A4S100A4SMN1; SMN2NPC1RAB9A
SCHEMBL18905 0.74 POLB (0.55) MAPTCYP1A2CYP3A4GAAS100A4
SCHEMBL5966127 0.74 KDM4E (0.35) TDP1HPGDMAPTALDH1A1KDM4E
SCHEMBL17438712 0.72 RAB9A (0.47) HPGDMAPTCYP1A2ALDH1A1KDM4E
SCHEMBL6469994 0.72 RAB9A (0.49) MAPTALDH1A1KDM4EGAACYP2C9
SCHEMBL6863661 0.72 ALDH1A1 (0.35) TDP1HPGDMAPTCYP1A2ALDH1A1
SCHEMBL1707607 0.71 RAB9A (0.41) TDP1HPGDMAPTCYP1A2ALDH1A1
SCHEMBL18230395 0.71 POLB (0.56) CYP1A2ALDH1A1CYP3A4SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283000-B1 3- OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS SK BIOPHARMACEUTICALS CO LTD (KR) 2015-09-23 EP disclosed
US-8546576-B2 3 or 4-substituted piperidine compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-10-01 US disclosed
US-8513285-B2 3 or 4-substituted piperidine compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-08-20 US disclosed
US-20120122927-A1 3 OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS LEE KI-HO (KR) 2012-05-17 US disclosed
EP-2283000-A2 3- OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS SK Holdings Co., Ltd. (KR) 2011-02-16 EP disclosed
US-20090306140-A1 3 or 4-Substituted Piperidine Compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-12-10 US disclosed
WO-2009148291-A2 3- OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS SK HOLDINGS CO., LTD. (KR) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122927-A1 3 OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS OPRD1, OPRK1, OPRM1 TDP1 1928/4885HPGD 403/4885SIRT2 2639/4885
US-20090306140-A1 3 or 4-Substituted Piperidine Compounds OPRD1, OPRK1, OPRM1 TDP1 1922/4885HPGD 426/4885SIRT2 2581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.